Usana Health Sciences stock plunged 30% this week after Q2 results missed analyst estimates and company issued disappointing guidance
The company reported adjusted earnings of $0.07 per share on sales of approximately $223 million for the second quarter, falling $0.50 below analyst EPS estimates and $12 million short on revenue. Usana also announced a $29 million goodwill impairment charge on its Hiya business, leading to a revised full-year forecast of an $11 million loss, down from previous guidance of $20 million to $27 million profit. Full-year sales guidance was also lowered from $925 million-$1 billion to $910 million.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
GRAM (Gram, prev. Toncoin) price pulls back to $1.057, hitting a nearly 365-day low
-
2
What is the LDN Token and How to Acquire and Trade It
-
3
A Review of Major Global Blockchain Trading Platforms and Apps
-
4
ANKR Token Analysis: Current State and Future Outlook of Web3 Infrastructure
-
5
Real-World Use Cases and Impact of Blockchain Brawlers (BRWL)
-
6
What Cryptocurrency Is ADR? A Deep Dive into the Solana Meme Project American Dollar Reserve
-
7
2026 US Stock Market Safe-Haven Assets Encyclopedia: How Walmart and Caterpillar Lead the Industrial Sector Amid AI Bubble Doubts
-
8
How is BFHT doing? What is the future outlook for BFHT?
-
9
Current Status of BUSD (Binance USD): Issuance Halted, Orderly Wind-Down Underway
-
10
BCH (Bitcoin Cash) trading volume reached $2.1 million over the past hour (15.2x its average for the same period over the past 7 days), currently trading at $247.900.
Markets Today
Recommended Reading






